This week's Fierce Biotech is brought to you by PA Consulting.

Trouble viewing? Click here.

Cell and Gene Therapy in 2040
Seizing today's moment to propel the industry forward.

Hi E,

We are delighted to share with you our latest discussion paper, Cell and Gene Therapy in 2040: Seizing today's moment to propel the industry forward.

Cell and Gene Therapy (C&GT) is one of the fastest growing markets in the life sciences sector, projected to reach $14 billion by 2025, and opening the door to treatments for numerous previously untreatable health conditions such as cancers and genetic disorders. At PA, the growth of the C&GT sector is something we have not just witnessed but have actively shaped over the past decade. To help leaders navigate the future, this report explores four potential FutureWorldsTM scenarios.
  • Bespoke World
  • Mass Market World
  • Eclipse World
  • Blocker World

We aim to inspire the future of medicine while teaching future leaders how to prepare for and shape it. There are many opportunities for C&GT, and the actions your organization takes now will influence your success while shaping the industry's future. This report will consider key topics such as early research, clinical trials, manufacturing and supply chain, regulations, reimbursement, and commercialization.

You can find out more about our work in the Life Sciences sector here.

If you'd like to discuss this report, please contact us at: [email protected]

Want to reach 137,000+ Fierce Biotech subscribers with your own message?
Contact [email protected] or call 202-824-5074.



You are currently subscribed as [email protected].
If you no longer wish to receive communications from Fierce Biotech's trusted partners, simply click here to unsubscribe.
Refer to our Privacy Policy.

Questex, LLC
685 3rd Avenue, 21st Floor  
New York, NY 10017